Synapsin Pharmaceuticals' Unattributed Round

Synapsin Pharmaceuticals raised a round of funding on July 20, 2016.

SYNAPSIN is developing therapeutic strategies for the treatmentand prevention ofneurodegenerative disorders such as Alzheimer's disease (AD),Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), a…

Articles about Synapsin Pharmaceuticals' Unattributed Round: